How a signaling enzyme controls heart adrenaline (beta) receptors
Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinase
This project looks at how a protein called PI3K changes the behavior of heart adrenaline (beta) receptors and how that may affect people with heart failure.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11239004 on NIH RePORTER |
What this research studies
From a patient's view, researchers are studying why heart adrenaline receptors stop working properly in heart failure and how a protein called PI3K alters a regulator (I2PP2A) of the phosphatase PP2A that normally restores those receptors. They will examine human heart tissue changes seen in people with heart failure and perform experiments in mice that mimic pressure-overload heart failure. The team uses molecular biology, biochemistry, and genetically modified mouse models to see whether blocking the harmful modification preserves receptor function and improves heart pumping. Findings will guide whether restoring this receptor resensitization could be a target for future treatments.
Who could benefit from this research
Good fit: Adults with diagnosed heart failure or people undergoing heart surgery who can donate tissue would be the most relevant candidates for related human studies.
Not a fit: People without heart failure or whose condition is unrelated to beta-adrenergic receptor dysfunction are unlikely to benefit directly from this research.
Why it matters
Potential benefit: If successful, this work could point to new therapies that restore heart adrenaline receptor function and improve outcomes in people with heart failure.
How similar studies have performed: Prior laboratory and animal studies support kinase and phosphatase control of beta receptors, and the specific PI3K–I2PP2A pathway is a newer finding with encouraging preclinical evidence.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Prasad, Sathyamangla V — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Prasad, Sathyamangla V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.